MY199945A - Vaccines against infectious diseases caused by positive stranded rna viruses - Google Patents
Vaccines against infectious diseases caused by positive stranded rna virusesInfo
- Publication number
- MY199945A MY199945A MYPI2019002595A MYPI2019002595A MY199945A MY 199945 A MY199945 A MY 199945A MY PI2019002595 A MYPI2019002595 A MY PI2019002595A MY PI2019002595 A MYPI2019002595 A MY PI2019002595A MY 199945 A MY199945 A MY 199945A
- Authority
- MY
- Malaysia
- Prior art keywords
- diseases caused
- rna viruses
- stranded rna
- infectious diseases
- vaccines against
- Prior art date
Links
- 208000035473 Communicable disease Diseases 0.000 title 1
- 241000700605 Viruses Species 0.000 title 1
- 229960005486 vaccine Drugs 0.000 title 1
- 241001493065 dsRNA viruses Species 0.000 abstract 3
- 239000000203 mixture Substances 0.000 abstract 2
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 abstract 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 210000003527 eukaryotic cell Anatomy 0.000 abstract 1
- 208000015181 infectious disease Diseases 0.000 abstract 1
- 230000002458 infectious effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5254—Virus avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/12—Type of nucleic acid catalytic nucleic acids, e.g. ribozymes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24141—Use of virus, viral particle or viral elements as a vector
- C12N2770/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24141—Use of virus, viral particle or viral elements as a vector
- C12N2770/24144—Chimeric viral vector comprising heterologous viral elements for production of another viral vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
- C12N2770/24151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/42—Vector systems having a special element relevant for transcription being an intron or intervening sequence for splicing and/or stability of RNA
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Molecular Biology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662426708P | 2016-11-28 | 2016-11-28 | |
| PCT/US2017/062733 WO2018098133A1 (en) | 2016-11-28 | 2017-11-21 | Vaccines against infectious diseases caused by positive stranded rna viruses |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MY199945A true MY199945A (en) | 2023-11-30 |
Family
ID=62195325
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MYPI2019002595A MY199945A (en) | 2016-11-28 | 2017-11-21 | Vaccines against infectious diseases caused by positive stranded rna viruses |
Country Status (7)
| Country | Link |
|---|---|
| US (3) | US11058759B2 (OSRAM) |
| EP (1) | EP3545083A4 (OSRAM) |
| JP (2) | JP7117015B2 (OSRAM) |
| KR (1) | KR102511472B1 (OSRAM) |
| CN (1) | CN110088273B (OSRAM) |
| MY (1) | MY199945A (OSRAM) |
| WO (1) | WO2018098133A1 (OSRAM) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4267171A4 (en) * | 2020-12-22 | 2025-05-21 | Seattle Children's Hospital (DBA Seattle Children's Research Institute) | Antigen-specific immunoregulatory artificial T cells (AIRT) |
| EP4317176A4 (en) | 2021-03-23 | 2025-04-16 | Virocure, Inc. | VACCINE COMPOSITION BASED ON AN ATTENUATED REOVIRUS AND USE THEREOF |
| CN114807232A (zh) * | 2022-05-12 | 2022-07-29 | 中国人民解放军海军军医大学 | 一株西尼罗病毒感染性克隆的构建及其应用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2941182A1 (en) | 2000-02-16 | 2001-08-23 | The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services | Avirulent, immunogenic flavivirus chimeras |
| US7455842B2 (en) * | 2005-12-05 | 2008-11-25 | University Of Kansas | Chimeric West Nile viruses and uses thereof |
| CN102600481A (zh) * | 2012-03-20 | 2012-07-25 | 中国农业科学院哈尔滨兽医研究所 | 腺病毒/日本脑炎病毒复制子嵌合载体猪瘟疫苗及其应用 |
| US9267114B2 (en) | 2012-11-07 | 2016-02-23 | Southern Research Institute | Flavivirus envelope protein mutations affecting virion disassembly |
| CN103088049A (zh) * | 2012-12-26 | 2013-05-08 | 中国人民解放军军事医学科学院生物工程研究所 | 日本脑炎病毒sa14-14-2株基于dna的感染性克隆、其构建方法及应用 |
| US10369209B2 (en) * | 2014-04-11 | 2019-08-06 | Utah State University | Drug target and construct for Japanese encephalitis virus infection |
-
2017
- 2017-11-21 KR KR1020197018792A patent/KR102511472B1/ko active Active
- 2017-11-21 WO PCT/US2017/062733 patent/WO2018098133A1/en not_active Ceased
- 2017-11-21 EP EP17873411.7A patent/EP3545083A4/en active Pending
- 2017-11-21 MY MYPI2019002595A patent/MY199945A/en unknown
- 2017-11-21 JP JP2019528043A patent/JP7117015B2/ja active Active
- 2017-11-21 CN CN201780073631.8A patent/CN110088273B/zh active Active
- 2017-11-21 US US16/462,383 patent/US11058759B2/en active Active
-
2021
- 2021-06-24 US US17/357,368 patent/US20210322535A1/en not_active Abandoned
- 2021-11-01 JP JP2021178709A patent/JP2022023198A/ja not_active Withdrawn
-
2024
- 2024-11-04 US US18/936,799 patent/US20250057932A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022023198A (ja) | 2022-02-07 |
| CN110088273A (zh) | 2019-08-02 |
| US11058759B2 (en) | 2021-07-13 |
| US20210322535A1 (en) | 2021-10-21 |
| EP3545083A1 (en) | 2019-10-02 |
| US20190314482A1 (en) | 2019-10-17 |
| JP7117015B2 (ja) | 2022-08-12 |
| JP2019535291A (ja) | 2019-12-12 |
| US20250057932A1 (en) | 2025-02-20 |
| KR102511472B1 (ko) | 2023-03-16 |
| CN110088273B (zh) | 2024-03-05 |
| KR20190092468A (ko) | 2019-08-07 |
| WO2018098133A1 (en) | 2018-05-31 |
| EP3545083A4 (en) | 2020-06-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12018500855A1 (en) | Herpes simplex virus vaccine | |
| MX2022006603A (es) | Vacuna contra el virus de la influenza de amplio espectro. | |
| EP4349404A3 (en) | Respiratory virus vaccines | |
| MX2022003116A (es) | Factor ix modificado, y composiciones, metodos y usos para la transferencia de genes a celulas, organos y tejidos. | |
| AU2016262093A8 (en) | Enhancing endonuclease based gene editing in primary cells | |
| MX2024008058A (es) | Adenovirus modificados. | |
| MX2016010649A (es) | Vector de virus adeno-asociado. | |
| EA202090994A1 (ru) | Композиции и способы ингибирования экспрессии генов вируса гепатита в | |
| EA201490627A1 (ru) | Соединения для улучшенной вирусной трансдукции | |
| EA201590868A1 (ru) | Противовирусные соединения | |
| EA201692359A1 (ru) | Композиция на основе нового штамма prrsv или его белков, продукт, их применение, вирус prrsv, выделенная нк и рекомбинантный вектор экспрессии для получения этого вируса | |
| NZ702146A (en) | Peptides derived from viral proteins for use as immunogens and dosage reactants | |
| MX383531B (es) | Novedoso bacteriófago clo-pep-1 de clostridium perfringens y su uso para inhibir la proliferación de clostridium perfringens | |
| PH12016500500A1 (en) | A viral vaccine and methods of manufacture thereof | |
| CL2018000164A1 (es) | Vector recombinante del virus orf. | |
| MY173638A (en) | Parainfluenza virus 5 based vaccines | |
| AU2007240448A8 (en) | Methods and compositions for expressing negative-sense viral RNA in canine cells | |
| UA108902C2 (uk) | Вірус північноамериканського репродуктивного та респіраторного синдрому свиней (prrs) та його застосування | |
| EP3939604A3 (en) | Influenza hemagglutinin protein vaccines | |
| WO2013030176A3 (en) | Live attenuated influenza virus | |
| EA202090628A1 (ru) | Система экспрессии paramyxoviridae | |
| BR112014015582A8 (pt) | compostos antivirais | |
| IN2014CN00572A (OSRAM) | ||
| MX2015016765A (es) | Celulas aviares para la produccion mejorada de virus. | |
| NZ726343A (en) | Antiviral compounds |